TAF II 105 is a sub-stoichiometric subunit of TFIID important for activation of anti-apoptotic genes and B cell specific genes by the transcription factors NF-B and OCA-B. This subunit is highly enriched in B and T lymphocytes, and its expression is regulated at a posttranscriptional level. In the present study we investigated the subcellular localization of TAF II to a CRM1-independent nuclear export pathway. These results reveal a novel mode of regulation of a specialized component of the general transcription apparatus that may affect the transcription of its target genes.
Transcription of class II genes involves the assembly of general transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) and RNA polymerase II around the transcription start site to form a pre-initiation complex (PIC). 1 The general transcription factor TFIID plays an important role in PIC formation, as it is responsible for recognition and binding to core promoter elements. TFIID is a multi-subunit complex consisting of TATA-binding protein (TBP) and associated factors (TAF II s). TAF II s play several important roles in transcription (reviewed in Refs. [1] [2] [3] . Certain TAF II s interact with activation domains of transcription factors transmitting their signal to the general transcription machinery. In addition, some of the TAF II s are required for recognition of and binding to core promoter elements such as the initiator and the downstream promoter element (4 -9) .
Biochemical analysis and x-ray crystallography of TAF II s showed that each subunit forms multiple contacts with other TAF II s in the complex, and many of these interactions are mediated through histone fold motifs (10) . Genetic studies in yeast carrying mutations in individual TAF II s subunits indicated that some TAF II s are required for transcription of the majority of class II genes and others for transcription activation of only subsets of genes (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Recently, some of the TAF II s were found to be integral components of other transcription regulatory complexes such as the yeast SAGA and human PCAF and TFTC (22, 23) .
TAF II 105 is a member of hTAF II 135 and dTAF II 110 family of TAF II s. It is expressed at high levels in cells of lymphoid origin relative to other tissues and cell types (24) . 2 Interestingly, recent data obtained from the human genome project revealed another gene on chromosome 4 encoding close homolog of TAF II 105 (accession number AC017007). The previously identified gene is located on chromosome 18 (accession number Y09321). As we found an EST clone identical to the chromosome 4 gene, it is likely that this gene is also expressed. Thus it appears that the family of these TAF II s is larger than initially anticipated.
Analysis of TAF II 105 function in cultured cells, in vitro and in an animal model provided evidence that it is involved in transcription activation by p65/RelA, a member of NF-B family (26 -28) 2 and OCA-B (29) . Both factors are required for lymphocyte gene expression. TAF II 105 is present only in a small fraction of TFIID complexes and is involved in transcription of a subset of genes (27) . 2 The C-terminal domain of hTAF II 105 is highly homologous to the C termini of hTAF II 135 and dTAF II 110 and is essential for assembly into the TFIID complex. 2 The N terminus of TAF II 105 is more variable and contains binding sites for the activation domains of p65/RelA and OCA-B (26, 29) . TAF II 105 expression is regulated at the posttranscriptional level since the mRNA levels of TAF II 105 in different cell types are similar, whereas a larger amount of protein is present in TFIID complex and in nuclear extracts of B cell lines than in non B cell lines (24) .
One way to regulate biological processes at the posttranscriptional level is by modulating the subcellular localization of the controlling proteins. The activity of nuclear proteins can be adjusted via their nuclear import or export. Nuclear transport in eukaryotic cell is triggered by specific transport signals that are recognized by receptors in the nuclear pore complexes (30) . Nuclear import is mediated by the nuclear localization signal (NLS) present in nuclear proteins. This process involves the * This research was supported by grants from the Association of International Cancer Research and by the Jakubskind-Cymerman Prize. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. (32) (33) (34) . The CRM1-NES interaction is Ran-GTP-dependent and GTP hydrolysis is required for triggering cytoplasmic dissociation of exported protein from CRM1 (reviewed in Ref. 35) . Another known NES is KNS that utilizes CRM1-independent pathway, and its sequence specificity distinguishes it from other nuclear transport signals (36) .
We have investigated the regulation of human and mouse TAF II 105 protein. We report that TAF II 105 is exported to the cytoplasm through a composite NES consisting of two adjacent and independent domains bearing nuclear export activity. TAF II 105 NES is resistant to the CRM1-specific inhibitor leptomycin B indicating that it is exported by a CRM1-independent nuclear export pathway. The results suggest that the subcellular localization of TAF II 105 is a useful mean of controlling TAF II 105 assembly into the TFIID complex and transcription of its target genes.
MATERIALS AND METHODS

Primary B Cell Culture Preparation and Activation
Single cell suspensions from spleen were prepared by crushing the organs in RPMI 1640 medium without serum followed by hypotonic lysis of erythrocytes. An enriched population of B cells was obtained from splenocytes by treatment with eliminating anti-CD4, anti-CD8, and anti-Thy-1 monoclonal antibody (Southern Biotechnology Associates, Inc., Birmingham, AL) and rabbit complement (Cedarline, Ontario, Canada). B cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum. Splenic B cells were stimulated with lipopolysaccharide (LPS) (10 g/ml, Sigma) or anti-IgM monoclonal antibody (25 g/ml, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).
Nuclear and Cytoplasmic Extracts Preparation and Immunoblot Analysis
Primary B Cells-Cells were counted, and 10 7 cells were precipitated and washed once with PBS and once with 1 ml of dialysis buffer (20 mM Hepes-KOH, pH 7.9, 20% glycerol, 0.2 mM EDTA, 2 mM dithiothreitol, 50 mM KCl, 5 mM Mg Cl 2 ). Cells were resuspended in 300 l of hypotonic buffer (25 mM Tris, pH 7.5, 5 mM KCl, 1.5 mM MgCl 2, 1 mM EDTA, 0.25% Triton X-100, 2 mM dithiothreitol) and incubated 10 min on ice. Soluble cytoplasmic proteins were obtained by centrifugation of lysates at 12,000 g for 2 min and collecting the supernatant. For nuclear proteins, the pellet was resuspended in 50 l of buffer C1 (20 mM Hepes-KOH, pH 7.9, 0.2 mM EDTA, 25% glycerol, 140 mM KCl, 2 mM dithiothreitol). The volume of resuspended pellet was measured, and an equal volume of buffer C2 (20 mM Hepes-KOH, pH 7.9, 0.2 mM EDTA, 25% glycerol, 700 mM KCl, 2 mM dithiothreitol) was added. The suspension was incubated on ice for 30 min and centrifuged at 12,000 g for 20 min. Supernatant containing nuclear proteins was collected. All buffers were supplemented with a mixture of protease inhibitors. Cell-equivalent amounts of extracts were loaded on 10% SDS-polyacrylamide gel followed by electrotransfer into nitrocellulose membrane. The membrane was blocked in PBST (PBS ϩ 0.1% Tween 20) containing 5% low fat milk for 1 h, incubated with primary antibodies diluted 1:2000 in PBST for 1 h, followed by 45 min of incubation with horseradish peroxidase-conjugated goat anti-rabbit antibodies (1:10,000 dilution). For detection Super-Signal reagent (Pierce) was used. Quantification was done using the Image-Gouge program (Fuji).
Adherent Cells-Cells were removed from the plates, washed with PBS, suspended in the 5 volumes of buffer A (10 mM Hepes, 1.5 mM MgCl 2 , 10 mM KCl, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, pH7.9) and incubated for 20 min on ice. After brief centrifugation cells were resuspended in 2 volumes of buffer A and lysed by passing through a syringe or by Dounce homogenizer followed by centrifugation. To the upper phase, cytoplasmic extract, 11% volume of buffer B (0.3 M Hepes, 1.4 M KCl, 0.03 M MgCl 2 ) was added. The pellet containing nuclei was suspended in buffer C (20 mM Hepes, 25% glycerol, 1.5 mM MgCl 2 , 0.42 M NaCl, 0.2 mM EDTA, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, pH7.9), Dounced in homogenizer, incubated on a rotator, and then centrifuged at 14,000 rpm for 30 min. The supernatant was dialyzed against buffer D (20 mM Hepes, pH 7.9, 0.1 M KCl, 2 mM MgCl 2, 0.2 mM EDTA, 20% glycerol, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride).
Cell Lines and Transfections
293T are human embryonic kidney fibroblasts expressing SV 40 large T antigen that allows expression of plasmids with SV 40 origin. Cells were maintained in Dulbecco's modified Eagles medium supplemented with 10% fetal calf serum, penicillin (200 I.U./ml), and streptomycin (100 g/ml). Transfections were performed by the calcium phosphate (CaPO 4 ) coprecipitation technique in 24-well plates containing 8 ϫ 10 4 293T cells/well. Transfection mixture contained 150 ng of expression vector. In each transfection the amount of cytomegaloviruscontaining plasmid was constant. Total DNA was kept to 1 g/well by supplementing with 850 ng of pUC18 DNA. Cells were harvested 24 -36 h after the transfection and subjected to immunostaining.
Expression Plasmids
TAF II 105 and various C-terminal truncated TAF II 105-expressing plasmids were described previously (27) . To construct TAF II 105⌬465-469 and TAF II 105(1-552)⌬465-469 expressing plasmid we employed PCR-based site-directed mutagenesis using QuikChange Site-Directed Mutagenesis Kit (Stratagene). We used pCGN-TAF II 105 and pCGN-TAF II 105(1-552) plasmids as templates and PCR Primers: 5Ј-GCA GTT CAA GTC AAG CAA CTA GTA GTT CAG CAG CCT TCA GG-3Ј; 5Ј-CCT GAA GGC TGC TGA ACT ACT AGT TGC TTG ACT TGA ACT GC-3Ј; pCGN-TAF II 105(1-475)⌬465-469 was obtained from the above reactions except that a point mutation after amino acid 475 yielded a stop codon. All the mutants were sequenced and analyzed for protein expression. GFP-(449 -475), GFP-(470 -495), and GFP-(495-540) were generated by insertion of a PCR fragment encoding 450 -475, 470 -495, and 495-540 amino acids of TAF II 105, respectively, into GFP-C3 vector (CLONTECH). These peptides were provided with BglII and BamHI restriction sites on their 5Ј-and 3Ј-ends and inserted into BglII restriction site of GFP-C3 vector. All fusions were sequenced to verify in-frame cloning and accuracy of sequence. The following PCR primers were used. 449 -475: upstream 5Ј-GAA GAT CTT TCA CAA CCA GCT GGG ATT CC-3Ј; downstream 5Ј-GGG GAT CCC CTG AAG GCT GCT GAA CTA C-3Ј. 470 -495: upstream 5Ј-GAA GAT CTG GTA GTT CAG CAG CCT TCA G-3Ј; downstream 5Ј-GGG GAT CCC ATT TCT GAA TGG TCA ATG-3Ј. 495-540: upstream 5Ј-GGA GAT CTG AAA TGT GGA CAG AAG ACG-3Ј; downstream 5Ј-GGG GAT CCA TTC TAT TTT TCT GAG TAG G-3Ј. Upstream primers contain BglII restriction site, and downstream primers contain BamHI site. GFP-MKK1 used as a positive control in our studies is a gift from R. Seger (Weizmann Institute).
Fluorescence Microscopy
HEK 293T cells were grown on coverslips coated with 20 g/ml poly-L-lysine (Sigma P1274) and harvested 24 h after transfection. The cells were fixed with 4% paraformaldehyde/PBS, rinsed, and blocked with blocking solution (TBS, 10% goat serum (Sigma G6767), 1% glycine, 2% bovine serum albumin, 0.05% Tween 20) . Cells were incubated with affinity-purified anti-TAF II 105 antibodies (1:100 dilution for endogenous protein and 1:200 dilution for transfected protein) for 1 h, rinsed in PBS, and incubated 1 h with secondary antibody (nitro blue tetrazolium, Alexa 488, A11034). The cells were rinsed again, incubated for 5 min with propidium iodide (2 ϫ 10 Ϫ4 mg/ml), and rinsed again. Samples were mounted with DAKO Fluorescent Mounting Medium (DAKO S3023). Photographs were taken at the ϫ60 objective.
Purification of the ␣-TAF II 105 Antibodies
GST-TAF II 105(1-552) was expressed in Escherichia coli and purified on glutathione beads. The protein was cross-linked to the beads in 0.2 M sodium borate, pH 9, by 20 mM dimethyl pimelimidate for 30 min at room temperature. The cross-linking was terminated by 2 h of incubation with 0.2 M ethanolamine, pH 8, and the beads were then washed with the equilibration buffer (0.5 M NaCl, PBS). The serum containing ␣-TAF II 105 antibodies was loaded onto TAF II 105 column. The beads were washed with washing buffer (0.5 M NaCl, PBS, 1% Nonidet P-40) and equilibrated again with equilibration buffer. The antibody was released from the antigen using the elution buffer (50 mM glycine, 0.15 M NaCl, pH 2.5). The pH value of the antibody was neutralized using 1 M Tris, pH 7.9, and the antibodies solution was dialyzed against PBS.
RESULTS
TAF II 105 Is Distributed in the Cytoplasm and the Nucleus of
Lymphocytes and Adherent Cells-TAF II 105 is highly expressed in the spleen and the thymus of the mouse. 2 To examine the subcellular localization of TAF II 105, cytoplasmic and nuclear extracts were prepared from normal mouse B cells isolated from spleen, and cell-equivalent amounts of these fractions were analyzed for the presence of TAF II 105 by immunoblot. As expected, most of TAF II 105 protein was nuclear; however, a significant portion was also seen in the cytoplasmic fraction (Fig. 1, lanes 1 and 6) . As TAF II 105 is a transcription factor its presence in the cytoplasm of resting B cells raises the possibility that its transport into and out of the nucleus may be regulated. Therefore we examined the effect of extracellular signals on TAF II 105 localization in B cells. We used LPS and anti-IgM antibodies to induce a mitogenic response in primary B cell. As the survival of the primary culture decreases with time resulting in lower number of live cells at late time points, we determined the ratio of nuclear to cytoplasmic levels of TAF II 105 protein at different time points after stimulation. The results (Fig. 1) indicate that B cell activation either by LPS or anti-IgM is associated with an increase in the relative amount of nuclear TAF II 105 compared with the cytoplasmic protein. As a control of nuclear and cytoplasmic extract preparation, a similar analysis was carried out with the same extracts using antibodies against OCT2, a B cell specific transcription factor. As shown in Fig. 1 (upper panel) OCT2 is found exclusively in the nuclear fraction. Since we did not observe appearance of degradation products of TAF II 105 in the cytoplasmic extracts of activated cells, it is likely that activation by LPS and anti-IgM affects the transport of TAF II 105 protein into or out of the nucleus.
Next we examined the intracellular location of TAF II 105 in HEK 293 cell line by immunostaining of the endogenous protein together with propidium iodide to visualize the nuclei ( Fig.  2A) and by immunoblot of fractionated extracts (Fig. 2C) . In the majority of the cells TAF II 105 was found accumulated in the nucleus. However, in some cells (5-7%) it was localized exclusively in the cytoplasm or dispersed throughout the whole cell. To confirm the specificity of TAF II 105 staining, HEK 293 cells were immunostained with an irrelevant primary rabbit polyclonal antibody purified by the same method, and only background staining was observed (data not shown). The background of the secondary antibody was also examined and found to be negligible (data not shown). A similar finding was observed using different fixing agents indicating that this phenomenon is not generated by the paraformaldehyde (data not shown). To validate the specificity of the cytoplasmic staining of TAF II 105, 293 cells were immunostained with monoclonal antibodies directed against p65/RelA together with anti-TAF II 105 antibodies. Fig. 2B shows a representative field of which p65/RelA is localized in the cytoplasm of non-stimulated cells consistent with previous reports, whereas TAF II 105 staining is nuclear in some cells or is cytoplasmic in others. Taken together, these results suggest that subcellular localization of TAF II 105 is regulated, and under certain circumstances it can be found in the cytoplasm.
TAF II 105 Contains Nuclear Export Signal-To investigate further the localization of TAF II 105, HEK 293 cells were transfected with a TAF II 105-expressing plasmid immunostained with TAF II 105 antibodies and observed by confocal microscopy (Fig. 3) . Transfected TAF II 105 is found both in the cytoplasm and the nucleus but, in contrast to the native protein, is more abundant in the cytoplasm. Nuclear staining can be clearly seen only in cells that express high amounts of TAF II 105 protein, whereas cytoplasmic TAF II 105 is seen in low expressing cells, indicating that localization in the cytoplasm is not caused by an excess of TAF II 105 expression. Cytoplasmic localization of TAF II 105 is also observed in fractionated extracts (Fig. 3B) . Thus, the possibility is raised that TAF II 105 may be exported from the nucleus through a NES.
To determine whether TAF II 105 bears a NES, we looked at the subcellular localization of several C-terminal deletion mutants of TAF II 105, reasoning that removal of NES would result in nuclear accumulation. Since the putative NLS of TAF II 105 is situated in the C terminus of the protein, an NLS derived from the SV-40 large T antigen was fused to all C-terminal-truncated TAF II 105 mutants. The mutants were transfected into HEK 293T cells and analyzed by immunostaining with TAF II 105-specific antibodies. As before, nuclei were visualized by propidium iodide staining (Fig. 4) . Notably, despite the presence of heterologous NLS, cellular distribution of TAF II 105(1-552) was similar to the full-length protein and found predominantly in the cytoplasm (Fig. 4, a-d) . A mutant truncated by a further 80 amino acids (TAF II 105(1-472)) was also excluded from the nucleus (Fig. 4, e and f) . With further deletion of 20 amino acids the mutant TAF II 105(1-452) showed nuclear localization (Fig. 4, g and h) . Expression of all mutants was also confirmed by immunoblot analysis of cell extract from the cells transfected with all mutants we used (data not shown). The results imply that TAF II 105 contains NES activity located between amino acids 452 and 472.
Search of the human genome data base revealed an additional gene on chromosome 4 encoding a close homolog of TAF II 105 (we named it TAF II 105␤ and the original gene as TAF II 105␣). As we found an EST clone (accession number BE936325) encoding for a DNA sequence identical to TAF II 105␤ it is likely that TAF II 105␤ is expressed. In addition, we found an EST clone (accession number AW297262) almost identical to TAF II 105␣. When we compared the region important for nuclear export between the three genes we found that TAF II 105␣ contains insertion of five amino acids (465-469) that are not present in TAF II 105␤ and EST clone AW297262 (Fig. 5A) . To examine whether these extra amino acids in TAF II 105␣ are important for nuclear export of this protein a deletion of these amino acids was introduced in TAF II 105(1-552) and TAF II 105(1-475) to generate TAF II 105(1-552)⌬465-469 and TAF II 105(1-475)⌬465-469. The new mutants were transfected into HEK 293T cells, and their localization was determined (Fig. 5B) . As before, TAF II 105(1-472) was mostly cytoplasmic (Fig. 5B, c and d) . However, TAF II 105(1-475)⌬465-469 was nuclear indicating that amino acids 465-469 are important for NES function. Interestingly, the same deletion in the context of TAF II 105(1-552) (Fig. 5B, a and b) or the full-length protein (data not shown) did not affect its cytoplasmic accumulation. One possible explanation of this result Immunostaining of HEK 293T cells transfected with TAF II 105 expression plasmid using anti-TAF II 105 primary antibodies followed by green fluorescent secondary antibody (green). Nuclear staining was performed using propidium iodide (red). Cells were visualized by confocal microscopy. Arrows point to cells expressing low levels of TAF II 105 that are predominantly cytoplasmic. B, analysis of transfected TAF II 105 in fractionated extracts as described in Fig. 2B . Densitometric quantification of the results indicated that 41.3% of transfected TAF II 105 is found in cytoplasmic fraction, whereas only 8.3% of TBP is cytoplasmic. is that in TAF II 105(1-552) there are additional sequence(s) contributing to its nuclear export, and disruption of one was not sufficient to prevent nuclear export. In TAF II 105(1-475) mutant there is only one NES so its disruption by deletion of amino acids 465-469 (FSLFH motif) abolishes export activity. Thus, a second NES must lie C-terminally to amino acid 475. This result suggests that the unique presence of the FSLFH sequence in TAF II 105␣ has a potential role in the control of its cellular localization. Remarkably the FSLFH motif is situated near the major NF-B binding site within TAF II 105. We found that deletion of this motif does not affect p65/RelA binding to TAF II 105 (the important sequence for p65/RelA binding is found within 454 -462 region that is conserved between all the homologs. 3 The proximity of these domains raised the possibility that NF-B binding and nuclear export protein binding with TAF II 105␣ may be mutually exclusive. However, co-transfection of p65/RelA with TAF II 105(1-552) did not significantly affect its localization possibly due to the presence of a second NES within TAF II 105A (data not shown).
TAF II 105 NES Is Composed of Two Domains-To characterize the NES of TAF II 105, we analyzed its activity in a heterologous system. The region containing the NES candidate sequences in TAF II 105 was divided into subdomains and fused to the GFP protein (Fig. 6) . The fusion proteins were transfected into HEK 293, and the expressed proteins were visualized by fluorescent microscopy. As shown, GFP stains cells homogeneously. Fusion of GFP to a fragment encoding for amino acid 495-540 of TAF II 105 resulted in distribution similar to that of GFP. The region encoding for amino acids 449 -475 exported GFP from the nucleus resulting in more cytoplasmic accumulation. Interestingly, the region of amino acids 470 -495 was also capable of driving GFP out of the nucleus. Since the mutant TAF II 105(1-475)⌬465-469 is located in the nucleus (Fig.  5) , the presence of amino acids 470 -475, which are common to both, is not sufficient to promote nuclear export. Thus, we suggest that TAF II 105 contains a nuclear export signal composed of two sequential and independent domains with nuclear export activity that are mapped to amino acids 449 -470 and 475-495.
The Effect of Leptomycin B on Nuclear Export of TAF II 105-Nuclear pore complex protein, CRM1, is able to recognize specific leucine-rich NESs and mediate protein export from the nucleus (reviewed in Ref. 33) . CRM1 is a target of the cytotoxin leptomycin B (LMB). By direct binding of LMB to CRM1, LMB disrupts NES-dependent nuclear export of proteins both in yeast and mammals (37) . In light of the data suggesting that TAF II 105 contains NES, we examined whether it is CRM1-dependent. We incubated cells transfected with full-length TAF II 105 or TAF II 105(1-552) for 2 h with 20 ng/ml LMB (Fig.  7) . There was no influence of LMB on the nuclear export of either full-length TAF II 105 or TAF II 105(1-552), whereas MKK1-GFP protein, whose export is known to be dependent on CRM1, (38, 39) accumulated in the nucleus in the presence of only 5 ng/ml LMB (Fig. 7, k-l) . We also examined the effect of LMB on each of TAF II 105 domains having nuclear export activity and found that neither of them directs nuclear export through CRM1 (data not shown). Thus TAF II 105 is exported from the nucleus to the cytoplasm through a pathway that is distinct from CRM1.
DISCUSSION
In the present study we investigated the subcellular localization of TAF II 105, a sub-stoichiometric subunit of TFIID complex. We found that TAF II 105 is able to shuttle between the nucleus to the cytoplasm, and this transfer is mediated by two adjacent nuclear export signals. Hence, it appears that the subcellular localization of components of the basal transcriptional machinery represents an additional mean of large-scale transcriptional control.
Fractionation of primary B cells revealed that TAF II 105 is localized in the nucleus and in the cytoplasm and that its cytoplasmic level is reduced in response to the mitogenic stim- uli LPS and anti-IgM. As we could not find signs of degradation of the cytoplasmic protein in response to LPS and anti-IgM, the presence of NES in TAF II 105 suggests that these extracellular stimuli inhibit its export from the nucleus. Given that induction of B cells, either by LPS or anti-IgM mimics antigenic stimulus to some extent, it is possible that TAF II 105 localization is associated with an immune response. This is consistent with its role in activation of subset of B cell-specific genes (28, 29) . 2 In adherent cultured cells immunostaining experiments showed that endogenous TAF II 105 might be localized either in the nucleus or the cytoplasm in some cells, whereas in others it is dispersed homogeneously throughout the cell. Such differences in TAF II 105 localization could be associated with the cell cycle stage of a given cell or with its physiological state. However, at present we were unable to link differential localization of TAF II 105 to a specific stage of the cell cycle (data not shown). Given that TAF II 105 is involved in activation of anti-apoptotic genes (26) 2 it is possible that this protein is excluded from the nucleus in cells undergoing apoptosis. Since only advanced apoptotic stages can be morphologically observed (reviewed in Ref. 25 There is a group of NESs composed of leucine-rich sequences known to be targeted by CRM1. TAF II 105 NESs were not influenced by the CRM1-specific inhibitor LMB, indicating that its export is mediated by a CRM1-independent pathway. Consistent with their LMB-independent function, these NESs are not similar to the consensus leucine-rich sequence. Since the field of nuclear export is relatively new, nuclear export of TAF II 105 may be directed by a new exportin receptor that recognizes specifically its NESs. Apparently, additional experiments are required to address the mechanism by which TAF II 105 is exported and the importance of its nuclear export. 
